Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
about
Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approachesAdoptive cell therapy for sarcoma"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer ImmunotherapyGraft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansionEngineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.NK cell-based immunotherapies in Pediatric Oncology.New frontiers in pediatric Allo-SCT.Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells.Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.New immunotherapeutic strategies for the treatment of neuroblastoma.Umbilical cord blood graft engineering: challenges and opportunities.More than the genes, the tumor microenvironment in neuroblastoma.Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21.Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity.Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.Engineering Natural Killer Cells for Cancer Immunotherapy.CD56 in the Immune System: More Than a Marker for Cytotoxicity?Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune CellsCytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cellsPotential of autologous NK cell therapy to eradicate leukemia: "Education is [not] the best provision for old age" -AristotleTGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.HLA-DR+ NK cells are mostly characterized by less mature phenotype and high functional activity.An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells.
P2860
Q26825652-75CC4186-6253-4819-88C4-9FA6368B86F1Q27009541-9EC85DDA-78A1-4504-ABBE-1DEF192443A6Q28081338-553DB79A-CD83-47EB-8EA0-6F57487163E8Q33770125-AF9CB0E7-2F57-4035-AF2A-09AEDE82FEEFQ33816097-BBD3D87D-0BE0-4047-B44C-C0923C2B0F6FQ34389202-D941957E-8FA3-43CF-B75B-8A3667B2F248Q34391263-A12A9353-C2A1-4881-AE1F-2446A24B4707Q35029441-626449F9-BDF4-4B67-B41B-E989D326C25DQ35600095-EA0985AF-C588-4CD0-91B7-9A0A5E8FECC9Q35600975-62EBDAA8-CAA3-4147-8F7B-A978870E4E21Q35628739-45C2FB7B-7A9F-425B-9C38-A0EB8F8C3412Q36317164-166AB788-015F-4B34-99DD-2DBD535499FCQ37718554-530A65EF-05FD-4784-A66C-D78AE3ADE926Q38389316-EB9DC719-2FF7-4276-90D2-82CF4ADFB01EQ38514503-1222BB7D-42FF-4275-A2BA-3030BF2F83A4Q38644731-44F47068-5F60-4429-B8FC-295939C65E11Q38771096-671FBE47-85B7-45F8-AF87-44A8A4CADFA6Q38857163-7C615BAF-C745-47CF-8154-C9A072CCD5F6Q38886708-E93A8116-883B-4935-873F-4260CB6A52F8Q38906557-EAEF93BD-45E9-4181-9A89-B19D4A39E53AQ39296861-F7AD05C1-5E66-41C1-A3D2-5777B6CCF56AQ39408704-E8872085-DAE5-44FD-A5BF-F5CBDE74CC21Q40101148-AA971229-C226-464A-9112-E38ACCC1607AQ41592643-BFE927FF-196A-472C-B8FC-1D8AA2DA2124Q41812231-19B9B749-AED7-4781-A08B-34EA5CE793ADQ42556477-4E211FE0-F566-4A39-879D-BCE46E611FE7Q42560899-5D0704C7-0E35-4FBA-BB1C-7881BD8514D6Q46462751-1B68D5D9-F58F-483C-A290-E2849DAD8A78Q47114749-B863EF20-5FBA-4EF7-8B6D-DB7BCE386B5BQ49834150-74AE722A-D004-44A4-B1D5-5BBA94F10165Q49884881-FA44243E-F8BB-4F93-A152-2F0927300333
P2860
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Growth and activation of natur ...... oma for adoptive cell therapy.
@en
type
label
Growth and activation of natur ...... oma for adoptive cell therapy.
@en
prefLabel
Growth and activation of natur ...... oma for adoptive cell therapy.
@en
P2093
P2860
P1476
Growth and activation of natur ...... oma for adoptive cell therapy.
@en
P2093
Dean A Lee
Hong-Wei Wu
Laurence J N Cooper
Michael A Sheard
Richard Sposto
Robert C Seeger
Srinivas S Somanchi
P2860
P304
P356
10.1158/1078-0432.CCR-12-1243
P407
P577
2013-02-01T00:00:00Z